A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy

S. Tafuto, G. Abate, P. D'Andrea, I. Silvestri, P. Marcelin, C. Volta, A. Monteverde, S. Colombi, S. Andorno, M. Aglietta

Research output: Contribution to journalArticle

Abstract

In order to obtain the beneficial effects from granulocyte-macrophage colony-stimulating factor (GM-CSF) on granulo-monocyte recovery with the minimum dose and toxicity, we compared the effect of two different GM-CSF schedules (5 μg/kg/day subcutaneously, days 5 to > 18 versus days 12 to > 18 on the cytopenias which follow cytostatic treatment with carboplatin (400 mg/m2 intravenous (i.v.) day 1) and etoposide (100 mg/m2 i.v. days 1 to > 3). 13 patients entered the study for a total of 36 evaluable cycles. The cytostatic treatment produced a neutropenia that persisted for up to day 22 (absolute neutrophil count (ANC) <1000/μl in 25% and ANC <2000 in 50% of control cycles). Early GM-CSF administration markedly increased the leucocyte nadir and produced two waves of leucocytosis: an early one, linked to marrow reserve release and presumably of no value to the patients; and a delayed one, due to marrow precursor and progenitor cell proliferation, in which the granulomonocytosis was associated with a marked eosinophilia. The delayed GM-CSF administration markedly increased the leucocyte nadir and accelerated granulo-monocyte recovery (with an only modest eosinophilia), so that chemotherapy could be repeated every 21 days in all the patients.

Original languageEnglish
Pages (from-to)46-49
Number of pages4
JournalEuropean Journal of Cancer
Volume31
Issue number1
DOIs
Publication statusPublished - 1995

Keywords

  • cancer chemotherapy
  • carboplatin
  • dose intensity
  • etoposide
  • GM-CSF
  • neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy'. Together they form a unique fingerprint.

  • Cite this